An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas
- PMID: 2569035
- DOI: 10.1002/path.1711580204
An immunohistochemical and in situ hybridization study of c-myc and c-erbB-2 expression in primary human breast carcinomas
Abstract
In previous studies of the expression and organization of proto-oncogenes in human breast a significant correlation has been found between amplification of c-myc and c-erbB-2 genes in carcinomas and poor short-term prognosis. Gene expression was estimated by analysis of total RNA from tissues, and similarly assessment of gene organization relied upon extraction of DNA from tissues. The present study has compared the expression of c-myc and c-erbB-2 mRNA as determined by in situ hybridization, and c-myc and c-erbB-2 protein expression detected by immunohistochemistry in a group of carcinomas for which there was knowledge of genomic organization and/or expression. Formalin-fixed, paraffin-embedded tissues of 38 carcinomas were assessed for the presence of c-myc protein, and 13 of these were examined for c-myc mRNA by in situ hybridization. Similarly processed tissue from 14 tumours was tested for c-erbB-2 protein using the antiserum 21N and ten of these carcinomas studied for c-erbB-2 mRNA localization. There was a good correlation between gene amplification, the presence of c-erbB-2 protein and mRNA: both the latter were detected in six of the seven carcinomas with an amplification but in none without. For some carcinomas there was a good correlation between c-myc protein and mRNA levels. Three carcinomas with gene amplification had a lower percentage of cells with detectable protein than showed hybridization for mRNA. Other carcinomas had a lower level of mRNA expression than protein. Neither approach could predict which carcinomas had amplification of the c-myc gene.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.Oncogene Res. 1988;3(1):21-31. Oncogene Res. 1988. PMID: 2905033
-
Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.Oncogene. 1991 Mar;6(3):431-7. Oncogene. 1991. PMID: 1707153
-
Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.Cancer Res. 1989 Dec 1;49(23):6675-9. Cancer Res. 1989. PMID: 2573420
-
The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).Anticancer Res. 1989 Sep-Oct;9(5):1265-79. Anticancer Res. 1989. PMID: 2686529 Review.
-
Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene.Pathol Annu. 1992;27 Pt 1:165-90. Pathol Annu. 1992. PMID: 1346551 Review.
Cited by
-
c-erbB-2 expression in different histological types of invasive breast carcinoma.J Clin Pathol. 1991 Mar;44(3):211-4. doi: 10.1136/jcp.44.3.211. J Clin Pathol. 1991. PMID: 1672872 Free PMC article.
-
Amplification and overexpression of the c-erbB-2 protooncogene in human gastric cancer.Gastroenterol Jpn. 1992 Apr;27(2):172-8. doi: 10.1007/BF02777719. Gastroenterol Jpn. 1992. PMID: 1577221
-
Preoperative assessment of prognostic factors in breast cancer.J Clin Pathol. 2001 Jan;54(1):20-4. doi: 10.1136/jcp.54.1.20. J Clin Pathol. 2001. PMID: 11271783 Free PMC article. Review.
-
In situ hybridisation in perspective.J Clin Pathol. 1991 Mar;44(3):177-81. doi: 10.1136/jcp.44.3.177. J Clin Pathol. 1991. PMID: 2013617 Free PMC article. Review.
-
c-erbB-2 oncogene product expression and prognosis in gastric carcinoma.J Clin Pathol. 1992 May;45(5):454-6. doi: 10.1136/jcp.45.5.454. J Clin Pathol. 1992. PMID: 1350789 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous